SOURCE: Global Communications Inc.

July 07, 2005 11:12 ET

Competitors Stem Cells Inc. (STEM) and U.S. Biodefense (UBDE) Separately Announce Milestone Neural Stem Cell Technology; California Institute for Regenerative Medicine Meet to Consider Guidelines

for State Funded Stem Cell Research in California

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Global Communications Inc.

FULLERTON, CA -- (MARKET WIRE) -- July 7, 2005 -- Stem Cell research continues to be a major health topic across the nation. Most recently there have been reports on strong support for the advancement of stem cell research, one example would be that recently Ohio Governor Bob Taft vetoed a bill that would ban funding for Embryonic Stem Cell research according to Medical News Today. In California the Scientific and Medical Accountability Standards Working Group meet to begin the public process of creating permanent standards for the California Institute for Regenerative Medicine.

Two most recent milestones in the advancement of Stem Cell research came yesterday as StemCells, Inc. (NASDAQ: STEM) announced that it has entered into an agreement with ReNeuron, a privately owned UK biotech corporation. The agreement enables ReNeuron to exploit its "c-mycER" conditionally immortalized adult human neural stem cell technology for therapy and other purposes. U.S. BioDefense (OTC BB: UBDE), being the second major public company to pioneer Neural Crest Stem Cell technology in the United States, also announced that it has signed a six (6) month option to license world patent application WO 03/054202 A1 and US patient application 5,958,767 entitled "Generation of Human Neural Crest Stem Cell Line and Its Utilization in Human Transplantation" and related applications with the University of British Columbia developed by Dr. Seung Kim in the Department of Neurology at UBC.

Other note worthy news came from Cord Blood America, Inc. (OTC BB: CBAI), an umbilical cord blood stem cell preservation company, who announced the launch of its Partners' Circle sales and marketing program. Geron Corporation (NASDAQ: GERN) recently announced the presentation of studies which demonstrate significant advancement of Geron's programs to develop human embryonic stem cell (hESC) based products for drug development and therapeutic applications. In 12 presentations from Geron scientists and collaborators at the International Society for Stem Cell Research (ISSCR) annual meeting in San Francisco, progress on the derivation of new hESC lines, along with the differentiation, characterization, transplantation, and manufacture of cells relevant for drug development and therapeutic applications will be reported.

About Global Communications, Inc.

Global Communications offers investor and market awareness services. Through proven techniques and a solid proprietary network of investors and professionals, Global Communications leverages its resources to maximize awareness and targeting return on investment. Global Communications, Inc. was paid cash by companies mentioned herein and may buy or sell the stock any time. Please visit our Section 17B disclaimer at

Contact Information

  • Contact:
    Global Communications, Inc.
    Heriberto Cruz
    Email: Email Contact
    Tel: 949.394.7495